⌘K
t
RTW Biotech Opportunities Ltd held its sixth Annual General Meeting on 9 June 2025, with all proposed resolutions duly passed without amendment. Shareholders approved the Audited Financial Statements, Directors' remuneration, re-elected William Simpson, Paul Le Page, Bill Scott, Baroness Nicola Blackwood, and Stephanie Sirota as Directors, and re-appointed KPMG Channel Islands Limited and KPMG LLP as auditors. Additionally, the Company was authorized to repurchase up to 49,896,260 Ordinary Shares, representing 14.99% of shares in issue, at a minimum price of US$0.01 per share until its 2026 AGM.
| Date | 9 Jun 2025 |
| Time | 16:00:01 |
| Category | AGMs and other meetings |
| ID | 0617M |
LEI: 549300Q7EXQQH6KF7Z84
9 June 2025
RTW BIOTECH OPPORTUNITIES LTD
(the "Company")
Results of the Annual General Meeting ("AGM")
The Company is pleased to announce that, at the sixth AGM held at 14.00 BST today, 9 June 2025, each of the Resolutions was duly passed without amendment.
The details of each resolution are as follows:
ORDINARY RESOLUTIONS
Resolution 1
IT WAS RESOLVED to receive and consider the Audited Financial Statements, the Directors' report, and the auditor's report for the financial year ended 31 December 2024.
|
For |
149,172,488 votes |
|
Against |
1,607 votes |
|
Withheld |
16,084 votes |
Resolution 2
IT WAS RESOLVED to approve the Directors' remuneration for the financial year ended 31 December 2024 as provided in the Directors' report.
|
For |
149,065,933 votes |
|
Against |
99,493 votes |
|
Withheld |
24,753 votes |
Resolution 31
IT WAS RESOLVED to re-elect William Simpson as a Director of the Company.
|
For |
480,796,845 votes |
|
Against |
22,288 votes |
|
Withheld |
34,696 votes |
Resolution 41
IT WAS RESOLVED to re-elect Paul Le Page as a Director of the Company.
|
For |
480,787,459 votes |
|
Against |
32,443 votes |
|
Withheld |
33,927 votes |
Resolution 51
IT WAS RESOLVED to re-elect Bill Scott as a Director of the Company.
|
For |
480,409,211 votes |
|
Against |
410,691 votes |
|
Withheld |
33,927 votes |
Resolution 61
IT WAS RESOLVED to re-elect Baroness Nicola Blackwood as a Director of the Company.
|
For |
480,797,614 votes |
|
Against |
22,726 votes |
|
Withheld |
33,489 votes |
Resolution 7
IT WAS RESOLVED to re-elect Stephanie Sirota as a Director of the Company.
|
For |
147,555,279 votes |
|
Against |
1,600,642 votes |
|
Withheld |
34,258 votes |
Resolution 8
IT WAS RESOLVED to re-appoint KPMG Channel Islands Limited and KPMG LLP as Auditor of the Company.
|
For |
149,139,600 votes |
|
Against |
27,622 votes |
|
Withheld |
22,957 votes |
Resolution 9
IT WAS RESOLVED to authorise the Board of Directors to determine the remuneration of the Auditor.
|
For |
149,156,787 votes |
|
Against |
13,246 votes |
|
Withheld |
20,146 votes |
As Special business
|
Resolution 10 IT WAS RESOLVED That the Company be and is hereby authorised, in accordance with section 315 of the Companies (Guernsey) Law, 2008, as amended (the "Companies Law"), subject to the Listing Rules made by the United Kingdom Financial Conduct Authority and all other applicable legislation and regulations, to make market acquisitions (within the meaning of section 316 of the Companies Law) of its own Ordinary Shares (as defined in the Company's Articles) which may be cancelled or held as treasury shares, provided that: i. the maximum number of Ordinary Shares authorised to be purchased under this authority shall be 49,896,260 Ordinary Shares (being 14.99 per cent. of the Ordinary Shares in issue as at the Latest Practicable Date, excluding any treasury shares); ii. the minimum price (exclusive of expenses) which may be paid for an Ordinary Share is US$0.01; iii. the maximum price (exclusive of expenses) which may be paid for an Ordinary Share shall be not more than an amount equal to the higher of (a) 5 per cent. above the average mid-market value of the Ordinary Shares on the regulated market where the repurchase is carried out for the five Business Days (as defined in the Company's Articles) prior to the day the purchase is made and (b) the higher of (i) the price of the last independent trade and (ii) the highest current independent bid price, in each case on the regulated market where the purchase is carried out; and
such authority to expire on the date which is 15 months from the date of passing of this resolution or, if earlier, at the end of the Annual General Meeting of the Company to be held in 2026 (unless previously renewed, revoked or varied by the Company by ordinary resolution), save that the Company may make a contract to acquire Ordinary Shares under this authority before its expiry which will or may be executed wholly or partly after its expiration and the Company may make an acquisition of Ordinary Shares pursuant to such a contract. |
||||||
|
|
||||||
|
|
||||||
|
Responses to investors' questions will be posted on the Company's website after the AGM.
¹ The Company notes that the voting rights adjustments under Article 6 and Article 23 of the Company's Articles of Incorporation were used in respect of resolutions 3, 4, 5 and 6, but this did not affect the outcome of the shareholder vote.
|
*A vote withheld is not a vote in law and is therefore not counted towards the proportion of votes "for" or "against" the Resolution.
Enquiries:
|
RTW Investments, LP - Investment Manager Woody Stileman (Business Development) Oliver Kenyon (Business & Corporate Development) Krisha McCune (Investor Relations)
|
+44 (0)20 7959 6361 biotechopportunities@rtwfunds.com |
|
Deutsche Numis - Joint Corporate Broker Freddie Barnfield Nathan Brown Euan Brown
|
+44 (0)20 7260 1000 |
About RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.